<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39384763</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-0105</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>NPJ vaccines</Title><ISOAbbreviation>NPJ Vaccines</ISOAbbreviation></Journal><ArticleTitle>Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections.</ArticleTitle><Pagination><StartPage>185</StartPage><MedlinePgn>185</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">185</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41541-024-00972-3</ELocationID><Abstract><AbstractText>The COVID-19 pandemic posed a challenge for people living with HIV (PLWH), particularly immune non-responders (INR) with compromised CD4 T-cell reconstitution following antiretroviral therapy (CD4 count &lt;350 cells per mm<sup>3</sup>). Their diminished vaccine responses raised concerns about their vulnerability to SARS-CoV-2 breakthrough infections (BTI). Our in-depth study here revealed chronic inflammation in PLWH and a limited anti-Spike IgG response after vaccination in INR. Nevertheless, the imprinting of Spike-specific B cells by vaccination significantly enhanced the humoral responses after BTI. Notably, the magnitude of cellular CD4 response in all PLWH was comparable to that in healthy donors (HD). However, the polyfunctionality and phenotype of Spike-specific CD8 T cells in INR differed from controls. The findings highlight the need for additional boosters with variant vaccines, and for monitoring ART adherence and the durability of both humoral and cellular anti-SARS-CoV-2 immunity in INR.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alirezaylavasani</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KG Jebsen Centre for B Cell Malignancies, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skeie</LastName><ForeName>Linda Gail</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egner</LastName><ForeName>Ingrid Marie</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Department of Immunology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KG Jebsen Centre for B Cell Malignancies, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chopra</LastName><ForeName>Adity</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ImmunoLingo Convergence Center, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahl</LastName><ForeName>Tuva Børresdatter</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Department of Immunology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prebensen</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaage</LastName><ForeName>John Torgils</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0003-0988-5768</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halvorsen</LastName><ForeName>Bente</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-6529-6485</Identifier><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lund-Johansen</LastName><ForeName>Fridtjof</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-2445-1258</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ImmunoLingo Convergence Center, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tonby</LastName><ForeName>Kristian</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reikvam</LastName><ForeName>Dag Henrik</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stiksrud</LastName><ForeName>Birgitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holter</LastName><ForeName>Jan Cato</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0003-1618-5022</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dyrhol-Riise</LastName><ForeName>Anne Ma</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-4009-4032</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munthe</LastName><ForeName>Ludvig A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-0344-3654</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Oslo University Hospital, Oslo, Norway. l.a.munthe@medisin.uio.no.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KG Jebsen Centre for B Cell Malignancies, University of Oslo, Oslo, Norway. l.a.munthe@medisin.uio.no.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway. l.a.munthe@medisin.uio.no.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kared</LastName><ForeName>Hassen</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-8220-997X</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Oslo University Hospital, Oslo, Norway. hassen.kared@medisin.uio.no.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KG Jebsen Centre for B Cell Malignancies, University of Oslo, Oslo, Norway. hassen.kared@medisin.uio.no.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway. hassen.kared@medisin.uio.no.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Vaccines</MedlineTA><NlmUniqueID>101699863</NlmUniqueID><ISSNLinking>2059-0105</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>23</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39384763</ArticleId><ArticleId IdType="pmc">PMC11464709</ArticleId><ArticleId IdType="doi">10.1038/s41541-024-00972-3</ArticleId><ArticleId IdType="pii">10.1038/s41541-024-00972-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abrams, E. M. &amp; Szefler, S. J. COVID-19 and the impact of social determinants of health. Lancet Respir. Med.8, 659–661 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7234789</ArticleId><ArticleId IdType="pubmed">32437646</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavanna, L., Citterio, C. &amp; Toscani, I. COVID-19 vaccines in cancer patients. Seropositivity and safety. Systematic review and meta-analysis. Vaccines9, 10.3390/vaccines9091048 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8473083</ArticleId><ArticleId IdType="pubmed">34579285</ArticleId></ArticleIdList></Reference><Reference><Citation>Galmiche, S. et al. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin. Microbiol. Infect.28, 163–177 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8595936</ArticleId><ArticleId IdType="pubmed">35020589</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, Y., Chen, Y., Liu, M., Shi, S. &amp; Tian, J. Impacts of immunosuppression and immunodeficiency on COVID-19: a systematic review and meta-analysis. J. Infect.81, e93–e95 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228685</ArticleId><ArticleId IdType="pubmed">32417309</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson, C. E., Kim, C., Weyand, C. M. &amp; Goronzy, J. J. Influence of immune aging on vaccine responses. J. Allergy Clin. Immunol.145, 1309–1321 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198995</ArticleId><ArticleId IdType="pubmed">32386655</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedicke, N. et al. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy. HIV Med.23, 558–563 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652991</ArticleId><ArticleId IdType="pubmed">34725907</ArticleId></ArticleIdList></Reference><Reference><Citation>Kared, H. et al. Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients. EBioMedicine97, 104833 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10585642</ArticleId><ArticleId IdType="pubmed">37844534</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte, K. I. et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit. Rev. Clin. Lab. Sci.59, 373–390 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935447</ArticleId><ArticleId IdType="pubmed">35220860</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoft, M. A., Burgers, W. A. &amp; Riou, C. The immune response to SARS-CoV-2 in people with HIV. Cell Mol. Immunol.21, 184–196 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10806256</ArticleId><ArticleId IdType="pubmed">37821620</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson, H. A., Kim, E. &amp; Badowski, M. E. A systematic review: impact of SARS-CoV-2 infection on morbidity, mortality, and viral suppression in patients living with HIV. SN Compr. Clin. Med. 5, 144 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10183680</ArticleId><ArticleId IdType="pubmed">37214621</ArticleId></ArticleIdList></Reference><Reference><Citation>Engsig, F. N. et al. Long-term mortality in HIV-positive individuals virally suppressed for &gt;3 years with incomplete CD4 recovery. Clin. Infect. Dis.58, 1312–1321 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6276895</ArticleId><ArticleId IdType="pubmed">24457342</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco, Y. M. et al. Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort. Antivir. Res. 117, 69–74 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25766861</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, L. et al. Cellular and molecular insights into incomplete immune recovery in HIV/AIDS patients. Front. Immunol.14, 1152951 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10185893</ArticleId><ArticleId IdType="pubmed">37205108</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks, S. G. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med.62, 141–155 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3759035</ArticleId><ArticleId IdType="pubmed">21090961</ArticleId></ArticleIdList></Reference><Reference><Citation>Moir, S. &amp; Fauci, A. S. B-cell responses to HIV infection. Immunol. Rev.275, 33–48 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5300048</ArticleId><ArticleId IdType="pubmed">28133792</ArticleId></ArticleIdList></Reference><Reference><Citation>Dandachi, D. et al. Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019. Clin. Infect. Dis.73, e1964–e1972 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499544</ArticleId><ArticleId IdType="pubmed">32905581</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassanjee, R. et al. COVID-19 among adults living with HIV: correlates of mortality among public sector healthcare users in Western Cape, South Africa. J. Int. AIDS Soc.26, e26104 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10281639</ArticleId><ArticleId IdType="pubmed">37339333</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesoriero, J. M. et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state. JAMA Netw. Open4, e2037069 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7859843</ArticleId><ArticleId IdType="pubmed">33533933</ArticleId></ArticleIdList></Reference><Reference><Citation>Wit, F. et al. COVID-19 in people with HIV in the Netherlands. AIDS37, 1671–1681 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10399951</ArticleId><ArticleId IdType="pubmed">37199566</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, X. et al. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV8, e690–e700 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8514200</ArticleId><ArticleId IdType="pubmed">34655550</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell, C. D., Lone, N. I. &amp; Baillie, J. K. Comorbidities, multimorbidity and COVID-19. Nat. Med.29, 334–343 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36797482</ArticleId></ArticleIdList></Reference><Reference><Citation>Cossu, M. V. et al. Comorbidity burden and suboptimal immunological responses to coronavirus disease 2019 vaccination in people living with human immunodeficiency virus. J. Infect. Dis.227, 733–735 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9278213</ArticleId><ArticleId IdType="pubmed">35796710</ArticleId></ArticleIdList></Reference><Reference><Citation>Verburgh, M. L. et al. Robust vaccine-induced as well as hybrid B- and T-Cell immunity across SARS-CoV-2 vaccine platforms in people with HIV. Microbiol. Spectr.11, e0115523 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10269828</ArticleId><ArticleId IdType="pubmed">37166335</ArticleId></ArticleIdList></Reference><Reference><Citation>El Chaer, F. &amp; El Sahly, H. M. Vaccination in the adult patient infected with HIV: a review of vaccine efficacy and immunogenicity. Am. J. Med.132, 437–446 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30611828</ArticleId></ArticleIdList></Reference><Reference><Citation>Remschmidt, C., Wichmann, O. &amp; Harder, T. Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety. Vaccine32, 5585–5592 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25131742</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortellini, E. et al. Immunogenicity and efficacy of vaccination in people living with human immunodeficiency virus. Viruses15, 10.3390/v15091844 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10534440</ArticleId><ArticleId IdType="pubmed">37766251</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenchley, J. M. &amp; Douek, D. C. HIV infection and the gastrointestinal immune system. Mucosal Immunol.1, 23–30 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2777614</ArticleId><ArticleId IdType="pubmed">19079157</ArticleId></ArticleIdList></Reference><Reference><Citation>Zicari, S. et al. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses11, 10.3390/v11030200 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6466530</ArticleId><ArticleId IdType="pubmed">30818749</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciabattini, A. et al. Evidence of SARS-CoV-2-specific memory B cells six months after vaccination with the BNT162b2 mRNA vaccine. Front. Immunol.12, 740708 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8505800</ArticleId><ArticleId IdType="pubmed">34650563</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science374, abm0829 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9284784</ArticleId><ArticleId IdType="pubmed">34648302</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte, K. I. et al. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: a systematic review. J. Med. Virol.94, 2939–2961 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9088566</ArticleId><ArticleId IdType="pubmed">35229324</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med.26, 1636–1643 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Kared, H. et al. Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults. Nat. Commun.13, 4165 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9293966</ArticleId><ArticleId IdType="pubmed">35851055</ArticleId></ArticleIdList></Reference><Reference><Citation>Doni, A. et al. The long pentraxin PTX3 as a link between innate immunity, tissue remodeling, and cancer. Front. Immunol.10, 712 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6459138</ArticleId><ArticleId IdType="pubmed">31019517</ArticleId></ArticleIdList></Reference><Reference><Citation>Garred, P. et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet349, 236–240 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9014910</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury, D. S. et al. Correlates of protection, thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection. Emerg. Infect. Dis.29, 381–388 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9881762</ArticleId><ArticleId IdType="pubmed">36692375</ArticleId></ArticleIdList></Reference><Reference><Citation>Coburn, S. B. et al. Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States. JAMA Netw. Open5, e2215934 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9175076</ArticleId><ArticleId IdType="pubmed">35671054</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, J. et al. Association between immune dysfunction and COVID-19 breakthrough infection After SARS-CoV-2 vaccination in the US. JAMA Intern. Med.182, 153–162 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8715386</ArticleId><ArticleId IdType="pubmed">34962505</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane, H. C. et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med.309, 453–458 (1983).</Citation><ArticleIdList><ArticleId IdType="pubmed">6224088</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Q. et al. Correlation between CD4 T-cell counts and seroconversion among COVID-19 vaccinated patients with HIV: a meta-analysis. Vaccines11, 10.3390/vaccines11040789 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10141854</ArticleId><ArticleId IdType="pubmed">37112701</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuan, J. J. et al. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV. HIV Med.23, 178–185 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652674</ArticleId><ArticleId IdType="pubmed">34632695</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockman, M. A. et al. Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults. J. Infect. Dis.225, 1129–1140 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689804</ArticleId><ArticleId IdType="pubmed">34888688</ArticleId></ArticleIdList></Reference><Reference><Citation>Costiniuk, C. T. et al. COVID-19 vaccine immunogenicity in people with HIV. AIDS37, F1–F10 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9794000</ArticleId><ArticleId IdType="pubmed">36476452</ArticleId></ArticleIdList></Reference><Reference><Citation>Heftdal, L. D. et al. Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV - a prospective observational cohort study. EBioMedicine93, 104661 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10272831</ArticleId><ArticleId IdType="pubmed">37331161</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy, I. &amp; Rahav, G. The effect of HIV on COVID-19 vaccine responses. Curr. Opin. HIV AIDS18, 135–141 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36943427</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorley-Lawson, D. A. &amp; Gross, A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med350, 1328–1337 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15044644</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehurst, C. B. et al. HIV co-infection augments EBV-induced tumorigenesis in vivo. Front. Virol.2, 10.3389/fviro.2022.861628 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9126505</ArticleId><ArticleId IdType="pubmed">35611388</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho, J. et al. Two overrepresented B cell populations in HIV-infected individuals undergo apoptosis by different mechanisms. Proc. Natl Acad. Sci. USA103, 19436–19441 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1748244</ArticleId><ArticleId IdType="pubmed">17158796</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryani, S. et al. Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. Blood115, 519–529 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19965666</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaspina, A. et al. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc. Natl Acad. Sci. USA103, 2262–2267 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413756</ArticleId><ArticleId IdType="pubmed">16461915</ArticleId></ArticleIdList></Reference><Reference><Citation>Estes, J. D. Pathobiology of HIV/SIV-associated changes in secondary lymphoid tissues. Immunol. Rev.254, 65–77 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6066369</ArticleId><ArticleId IdType="pubmed">23772615</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med.385, e84 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Alos, L. et al. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat. Commun.13, 1614 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8960902</ArticleId><ArticleId IdType="pubmed">35347129</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature602, 657–663 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim, S. S. A. &amp; Karim, Q. A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet398, 2126–2128 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8640673</ArticleId><ArticleId IdType="pubmed">34871545</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature602, 676–681 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35016198</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature599, 114–119 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8566220</ArticleId><ArticleId IdType="pubmed">34488225</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature596, 276–280 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34237773</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergori, A. et al. Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV. Nat. Commun.13, 4922 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9395398</ArticleId><ArticleId IdType="pubmed">35995780</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergori, A. et al. Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV. Int. J. Infect. Dis.134, 195–199 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10277256</ArticleId><ArticleId IdType="pubmed">37343783</ArticleId></ArticleIdList></Reference><Reference><Citation>Alrubayyi, A. et al. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. Nat. Commun.12, 5839 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8492866</ArticleId><ArticleId IdType="pubmed">34611163</ArticleId></ArticleIdList></Reference><Reference><Citation>Donadeu, L. et al. Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV. AIDS36, 1373–1382 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35730384</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso, M. J. et al. Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection. AIDS36, F7–F16 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9444925</ArticleId><ArticleId IdType="pubmed">35866847</ArticleId></ArticleIdList></Reference><Reference><Citation>Riou, C. et al. Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection. J. Clin. Invest. 131, 10.1172/JCI149125 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8203446</ArticleId><ArticleId IdType="pubmed">33945513</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, Y. et al. Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study. EClinicalMedicine43, 101226 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8642727</ArticleId><ArticleId IdType="pubmed">34901799</ArticleId></ArticleIdList></Reference><Reference><Citation>Frater, J. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV8, e474–e485 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8213361</ArticleId><ArticleId IdType="pubmed">34153264</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, X. et al. Comparing immune responses to inactivated vaccines against SARS-CoV-2 between people living with HIV and HIV-negative individuals: a cross-sectional study in China. Viruses14, 10.3390/v14020277 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8875274</ArticleId><ArticleId IdType="pubmed">35215870</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyaert, M. et al. Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients. Front. Immunol.13, 858399 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8988283</ArticleId><ArticleId IdType="pubmed">35401575</ArticleId></ArticleIdList></Reference><Reference><Citation>Woldemeskel, B. A. et al. The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human Immunodeficiency Virus (HIV). Clin. Infect. Dis.74, 1268–1270 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406881</ArticleId><ArticleId IdType="pubmed">34293114</ArticleId></ArticleIdList></Reference><Reference><Citation>Antinori, A. et al. Humoral and cellular immune response elicited by mRNA vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in people living with human immunodeficiency virus receiving antiretroviral therapy based on current CD4 T-lymphocyte count. Clin. Infect. Dis.75, e552–e563 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047161</ArticleId><ArticleId IdType="pubmed">35366316</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature603, 488–492 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8930768</ArticleId><ArticleId IdType="pubmed">35102311</ArticleId></ArticleIdList></Reference><Reference><Citation>Redd, A. D. et al. Minimal crossover between mutations associated with Omicron variant of SARS-CoV-2 and CD8(+) T-cell epitopes identified in COVID-19 convalescent individuals. mBio13, e0361721 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8941890</ArticleId><ArticleId IdType="pubmed">35229637</ArticleId></ArticleIdList></Reference><Reference><Citation>Redd, A. D. et al. CD8+ T-cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. Open Forum Infect. Dis.8, ofab143 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083629</ArticleId><ArticleId IdType="pubmed">34322559</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell185, 847–859.e811 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784649</ArticleId><ArticleId IdType="pubmed">35139340</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol.23, 186–193 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallajosyula, V. et al. CD8(+) T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients. Sci. Immunol.6, 10.1126/sciimmunol.abg5669 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8975171</ArticleId><ArticleId IdType="pubmed">34210785</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng, Y. et al. An immunodominant NP(105-113)-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nat. Immunol.23, 50–61 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8709787</ArticleId><ArticleId IdType="pubmed">34853448</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranbhai, V. et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell185, 1041–1051.e1046 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8810349</ArticleId><ArticleId IdType="pubmed">35202566</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemet, I. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N. Engl. J. Med.386, 492–494 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8823651</ArticleId><ArticleId IdType="pubmed">34965337</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryawanshi, R. K. et al. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature607, 351–355 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9279157</ArticleId><ArticleId IdType="pubmed">35584773</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrati, C. et al. Persistent spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine. Sci. Rep.12, 6687 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034067</ArticleId><ArticleId IdType="pubmed">35461335</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, F. et al. Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8(+) T cell responses post SARS-CoV-2 infection. Immunity56, 864–878.e864 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10017386</ArticleId><ArticleId IdType="pubmed">36996809</ArticleId></ArticleIdList></Reference><Reference><Citation>Korencak, M. et al. Effect of HIV infection and antiretroviral therapy on immune cellular functions. JCI Insight4, 10.1172/jci.insight.126675 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6629105</ArticleId><ArticleId IdType="pubmed">31217351</ArticleId></ArticleIdList></Reference><Reference><Citation>Maslo, C. et al. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. JAMA327, 583–584 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8719272</ArticleId><ArticleId IdType="pubmed">34967859</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L. et al. Characterizing distinct profiles of immune and inflammatory response with age to Omicron infection. Front. Immunol.14, 1189482 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10348361</ArticleId><ArticleId IdType="pubmed">37457688</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell, J. H., Hearps, A. C., Martin, G. E., Williams, K. C. &amp; Crowe, S. M. The importance of monocytes and macrophages in HIV pathogenesis, treatment, and cure. AIDS28, 2175–2187 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331181</ArticleId><ArticleId IdType="pubmed">25144219</ArticleId></ArticleIdList></Reference><Reference><Citation>Msomi, N., Lessells, R., Mlisana, K. &amp; de Oliveira, T. Africa: tackle HIV and COVID-19 together. Nature600, 33–36 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34853449</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim, F. et al. Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation. Nat. Commun.15, 2360 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10943233</ArticleId><ArticleId IdType="pubmed">38491050</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso, M. J., Bakkour, S., Busch, M. P., Deeks, S. G. &amp; Henrich, T. J. A high percentage of people with human immunodeficiency virus (HIV) on antiretroviral therapy experience detectable low-level plasma HIV-1 RNA following coronavirus disease 2019 (COVID-19). Clin. Infect. Dis.73, e2845–e2846 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717237</ArticleId><ArticleId IdType="pubmed">33211091</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer, M. et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA315, 801–810 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Holter, J. C. et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc. Natl Acad. Sci. USA117, 25018–25025 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7547220</ArticleId><ArticleId IdType="pubmed">32943538</ArticleId></ArticleIdList></Reference><Reference><Citation>Jyssum, I. et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol.4, e177–e187 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8700278</ArticleId><ArticleId IdType="pubmed">34977602</ArticleId></ArticleIdList></Reference><Reference><Citation>Sikorski, K. et al. A high-throughput pipeline for validation of antibodies. Nat. Methods15, 909–912 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30377371</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, W. et al. Antibody array analysis with label-based detection and resolution of protein size. Mol. Cell Proteom.8, 245–257 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">18796702</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>